Genome Editing and Engineering

Genome engineering turns the reading of DNA into the rewriting of it, using programmable tools that cut DNA at chosen sites so that sequences can be deleted, corrected, or inserted with precision.

Definition

Genome editing is the targeted alteration of an organism's DNA at a chosen site using programmable nucleases, most prominently the CRISPR-Cas system, in which a guide RNA directs an enzyme to cut a matching sequence.

Scope

This topic covers the foundations of recombinant DNA technology, the targeted nucleases that preceded CRISPR, the CRISPR-Cas9 system and how a guide RNA directs cleavage, the repair pathways that finalize an edit, base and prime editing, and the major applications and ethical considerations of editing genomes. It treats the deliberate modification of genomes; the natural sources of sequence change are covered under mutation and recombination.

Core questions

• How does a guide RNA direct the Cas9 enzyme to a specific DNA sequence?
• How do cellular repair pathways turn a targeted cut into a deletion or a precise correction?
• How do base and prime editing change DNA without making a double-strand break?
• What applications and ethical concerns arise from the ability to edit genomes?

Key concepts

• Recombinant DNA and earlier targeted nucleases
• CRISPR-Cas9 and guide-RNA targeting
• Repair by non-homologous end joining and homology-directed repair
• Base editing and prime editing
• Applications and ethics of editing

Mechanisms

In CRISPR editing, a short guide RNA base-pairs with a target DNA sequence and positions the Cas9 nuclease to cut both strands; the cell then repairs the break either by error-prone end joining, which can disrupt a gene, or by homology-directed repair using a supplied template, which can install a precise change, while base and prime editors chemically convert or rewrite bases without a full double-strand break.

Clinical relevance

Genome editing has produced approved therapies for inherited blood disorders, drives research into correcting disease-causing mutations and engineering cell therapies, and raises significant ethical questions, especially around heritable editing of the human germline; this entry is educational and not a guide to clinical use.

History

Recombinant DNA techniques of the 1970s first allowed genes to be cut and joined, zinc-finger and TALEN nucleases brought programmable targeting in the 2000s, and the 2012 demonstration that CRISPR-Cas9 could be programmed with a guide RNA made precise editing simple and widespread, earning Doudna and Charpentier the 2020 Nobel Prize in Chemistry.

Debates

Heritable human germline editing

Editing embryos or germ cells would pass changes to future generations, raising unresolved questions about safety, consent, equity, and the line between treatment and enhancement; most authorities currently regard clinical germline editing as premature and ethically fraught.

Key figures

• Jennifer Doudna
• Emmanuelle Charpentier
• Feng Zhang

Seminal works

• jinek2012

Frequently asked questions

How does CRISPR know where to cut?

A short guide RNA carries a sequence matching the intended target; it base-pairs with that DNA and brings the Cas9 enzyme to the right spot, so changing the guide RNA reprograms the system to cut a different sequence.

Is CRISPR editing always precise?

Editing can have off-target effects and the repair of a cut is not fully controllable, which is why newer approaches such as base and prime editing aim for greater precision and why safety evaluation is central to any therapeutic use.